|
PDS01ADC Clinical Trials
5 actively recruiting trials across 1 location
▼ -1 trial since August 2026
Pipeline
Phase 2: 3Phase 1/2: 2
Top Sponsors
- National Cancer Institute (NCI)5
Indications
- Cancer5
- Cancer of Prostate2
- Liver Disease1
- Prostate Neoplasms1
- Adrenal Cortex Neoplasms1
Bethesda, Maryland5 trials
A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer
National Institutes of Health Clinical Center
Phase 1/2
A Phase II Study Evaluating T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine PDS01ADC in Localized High and Intermediate Risk Prostate Cancer Treated With Androgen Deprivation Therapy
National Institutes of Health Clinical Center
Phase 2
Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy
National Institutes of Health Clinical Center
Phase 2
PDS01ADC Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma
National Institutes of Health Clinical Center
Phase 1/2
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
National Institutes of Health Clinical Center
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.